BioGaia’s former subsidiary Infant Bacterial Therapeutics AB (IBT) was
distributed from BioGaia and commenced trading on Nasdaq First North on March 29
2016. IBT has today announced a rights issue of approximately SEK 100 million.
To ensure the rights issue, BioGaia will guarantee the issue on market-based
conditions up to an amount of SEK 38 million. BioGaia wishes to give IBT and its
shareholders favourable circumstances for a successful share issue. The proceeds
from the issue will be used for clinical studies to be started in the near
future.
In the event that BioGaia’s guarantee is utilised, the holding will be handled
as a financial asset and sold on at appropriate moments.
Latest press releases from BioGaia
2016-04-25 BioGaia’s oral health probiotics to be launched in Hong Kong
2016-04-06 Notice to attend the Annual General Meeting of BioGaia AB (publ)
2016-03-18 Extraordinary General Meeting of BioGaia AB
BioGaia has published this information in accordance with the Swedish Securities
Act. The information was issued for publication on 27 April 2016, 8:15 am CET.
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
